ERBB2 and metastatic malignant neoplasm: The HER2 protein, which is upregulated as a result of high-level ERBB2 amplification, is a druggable target, and the HERACLES trial demonstrated a 30% response rate to dual HER2 blockade in the 5% subpopulation of HER2 positive and KRAS wild-type metastatic cancers [5].